Published in Health Business Week, September 2nd, 2005
Adeza reported record quarterly product sales of $10.6 million for the second quarter of 2005, an increase of 27% from product sales of $8.4 million for the second quarter of 2004. This increase is primarily attributed to higher sales volume of FullTerm, The Fetal Fibronectin Test.
Net income for the second quarter of 2005 increased by 40% to $1.8 million, compared with net income of $1.3 million for the second quarter of 2004, marking the company's 12th consecutive profitable quarter.
Diluted earnings per share for the second quarter of 2005 was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2005-09-02)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.